

## Index

### **a**

- Abl SH3 domain 241  
 AB variant of GM2 gangliosidosis 75  
 AcA thioester 231  
 acetamidomethyl (Acm) 121, 233  
 acetamidomethyl (Acm) Cys protecting group 196  
 acetamidomethyl group (Acm) 262  
 acetoacetyloxime (AcA) linker 272  
 acetoacetyl (AcA) purification 231  
 acetonitrile (ACN) 185  
 acetylated histone H4 501  
 acetylation 393, 499, 502  
*N*-acetylation 212  
 acetylcholine 344  
*N*-acetylglucosamine 137  
*p*-acetyl-L-phenylalanine 333  
 acidic sodium acetate buffer 261  
 acid-sensing ion channels (ASIC) 101  
 acid-sensitive CTC-resin 95  
 acid-stable C-terminal glycolamide-ester 193  
 ACP(65-74) 39, 49  
 ACP(65-74) peptide 27  
 activity-based probes (ABPs) 403  
 acyl azide 88  
 acyl azide-based coupling method 88  
 acyl azide-based solid phase peptide synthesis 88  
 acyl azide-based solution phase peptide synthesis 89  
*N*-acyl-benzimidazolinone (Nbz) 169, 295  
 acyl donors 63  
 $\gamma$ -acyloxy Gln variant 139  
 acetylacetone (acac) 94  
 additive-free diselenide-selenoester ligation 174  
 African swine fever virus polymerase X (ASFV pol X) 113  
 aldehyde-derivatized agarose 229  
 aldehydes 328  
 ALFALFA 39  
   peptide 27  
*p*-alkoxybenzyl-oxycarbonyl hydrazide resin 91  
 alkyl/aryl thioesters 61  
 alkyl/aryl thiols 61  
*N*-alkylated 2-bromoethylamine derivative 111  
*N*-alkylated peptide hydrazide 240  
*N*-alkylcysteine 61  
 alkyl propylthioesters 164  
 alkyl thioesters 71  
 alloc-protected Phacm linker 197  
 alloc-protected phenylactamidomethyl group 196  
 allo-isoleucine 367  
 allosteric effects 377  
 allyl alcohol 139  
 allyl iodoacetate 214  
*N*-allyloxycarbonyl (Aloc) group 263  
 allyloxy carbonyl (Alloc) protecting group 189  
 Aloc-protected Aoa 266  
 amide-cyclized peptides 99

- amide-to-ester substitutions 359–361  
amide-to-thioester modification 359  
amine 191  
amine-containing sulfonylethylcarbonate  
  building block 270  
 $\alpha$ -amine peptide bond 188  
aminoacetaldehyde dimethylacetal 237  
amino acid Boc-hydrazine 88  
135 amino acid HA-tagged human histone  
  2B (H2B) derivative 265  
84-amino acid human parathyroid  
  hormone 187  
28 amino acid knottin EETI-II 265  
D-amino acid peptidase 189  
61 amino acid polypeptide 266  
*d*-amino acids 519  
L-amino acids 519  
amino acid sequence 1, 2, 4, 9  
aminoacyl-*N*-hydroxyl group 302  
 $\gamma$ -amino alcohol 298  
 $\gamma$ -amino alcohol-based ligation 302  
1, 2-aminoalcohols 329  
amino-containing peptide segments 90  
8-amino-3,6-dioxaoctanoate (ADO) 194  
aminomethyl ChemMatrix® resin 70  
aminoxy-derivatized resin 227, 233  
aminoxy functionalization 335, 337  
aminoxy-functionalized cellulose solid  
  support 266  
aminoxy-functionalized SPCL solid  
  support 272  
aminoxy resin 231  
 $\beta$ -amino thioester 268  
amyloid beta (A $\beta$ ) 193  
amyloid 'switch' peptides 189  
animal toxins 101  
anti-diastereomer 133, 149  
antifreeze glycoprotein (AFGP) 432, 433  
antigenic peptide 101  
anti-HIV therapeutic Enfuvirtide 137  
antimicrobial peptide RTD-1 176  
arginine 139  
Arg<sub>3</sub> solubilizing tag 196  
Arg<sub>4</sub>-tagged RBM group 298  
aryl aldehyde esters 289  
aryl-selenoester functionalized fragment  
  147  
aryl thioesters 162  
arylthiol catalyst 4  
asparagine 135  
aspartic acid 89, 122, 139, 147  
aspartic acid ligation 298  
aspartyl aldehyde (Asa) linkage 245  
Asx/Glx residues 197  
asymmetric disulfide 133  
ATP synthase 442  
automated fast flow peptide synthesis 19  
  first generation 21–24  
  fourth generation 45–49, 50  
  second generation 24–32  
  third generation 32–45  
automated fast flow peptide synthesizer  
  (AFPS) 19  
autophagosomal marker protein LC3-II  
  195  
autoubiquitination 311  
auxiliary salicylaldehyde 302  
avidin-functionalized sepharose beads  
  268  
axinastatin 1 168  
azide-protected N-terminal serine 295  
1-azido-5-[1,3-dimethyl-2,4,6-(1*H*,3*H*,5*H*)-  
  trioxypyrimidine-5-ylidene]pentyl  
  (N<sub>3</sub>-Dtp) 272  
2-(2-azido-ethoxy)-ethanol 241  
(2-[2-(2-azido-ethoxy)-ethyl-sulfonyl]-2-  
  ethoxycarbonyl linker (N<sub>3</sub>-Esoc)  
  271
- b**
- Bacillus amyloliquefaciens 317  
Bacillus amyloliquefaciens RNase 178  
backbone-amide-linker (BAL) strategy  
  241  
backbone engineering  
  approach 522  
   $\beta$ -sheet assembly 520  
  consequences of chirality 517–520  
  control folding 520–522  
  facilitate synthesis 516–517

- protein mimetics 522–525
- base-catalyzed Henry reaction 131
- base-labile 4-hydroxymethylbenzoic acid (HMBA) linker 267
- base-labile sulfonylethoxycarbonyl moiety 221
- benzoylglycine 88
- benzyl alcohol 149
- benzyl cinnamate 127
- benzyloxycarbonyl (Cbz) group 189
- bicyclic thiolactone-promoted internal activation strategy 169
- bicyclic turndipeptide (BTD) 521
- bicyclononyne-functionalized resin 242
- bifunctional middle fragment 147
- bifunctional peptide 71, 78
- bifunctional SEA<sup>off</sup> and SeEA<sup>off</sup> containing peptides 69
- bifunctional SEA peptide 72
- binding assays 311
- bioactive human chemokine hCCL21 99
- bioactive peptide LacZ $\alpha$  94
- bioconjugation 297
- biologically active glycoproteins 105
- biomimetic polymers 17
- biopolymers 17
- biosourced oligosaccharide-based polymers 276
- biotinylated analogue of the HGF/SF NK1 domain 71
- biotinylated Cys peptide 74
- biotinylated HGF 231
- biotinylated Lys residue 268
- bis(2-sulfanylethyl) amide (SEA) system 63, 164
- bis(2-selanylethyl)amido group (SeEA) 63
- bis(2-selanylethyl)amine 68
- bis(2-sulfanylethyl)amine 68
- bis(2-selanylethyl)amine diselenide precursor 68
- bis(2-sulfanylethyl)amine trifluoroacetic acid salt 68
- bis(2-sulfanylethyl)-amino (SEA) ligation method 189
- bis(acetoxy)iodobenzene (BAIB) 151
- 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 39
- bisphosphorylated p62 to K63 diubiquitin 105
- bis-(2-sulfanylethyl)amido group (SEA) 270
- bis-sulfoxide 266
- Boc-aminooxy acetic acid 336
- Boc-Asp-OtBu 130
- Boc-Asp(OtBu)-OAll amino acid 147
- Boc-Asp(OAll)-OH 135
- Boc-Asp(OAll)-OMe 137
- Boc-based SPPS 167
- Boc/Bzl-solid phase peptide synthesis (SPPS) 360
- Boc-carbamate 151
- Boc chemistry 2
- Boc-Glu(OtBu)-OAll 124
- Boc-Lys-OH 93
- Boc-N-methyl-N-[2-(methylamino)ethyl] carbamoyl (Boc-Nmec) 195
- Boc-N-methyl-N-[2-(methylamino)-ethyl]-carbamoyl group 194
- Boc-Sec<sub>2</sub>-OH dimer 147
- Boc-SPPS 438, 449, 450, 453, 454, 559, 562, 563, 566
- 9-borabicyclononane (9-BBN) 133
- p*-boronobenzyloxycarbonyl (Dobz) 502
- p*-boronobenzyloxycarbonyl (Dobz)-protected Cys 96
- bovine pancreatic ribonuclease 90
- bovine pancreatic trypsin inhibitor (BPTI) 191, 369, 476
- Bowman Birk inhibitors (BBIs) 559
- BPN 317, 318
- $\beta$ -branched Thr and Leu 174
- $\beta$ -branched valine 161
- bromoacetic acid 268
- N*-bromosuccinimide (NBS) 125
- building blocks 195
- bulky amino acid side chains 18
- bulky C-terminal residues 161
- bulky valinylthioesters 173

- butelase-1 316, 317  
*tert*-butoxy carbonyl (Boc) 554  
*tert*-butoxycarbonyl hydrazide 89  
*n*-butyl nitrite 88  
*tert*-butyl nitrite 90  
*tert*-butyloxycarbonyl (Boc)-protecting the imidazole ring (im) 20
- C**
- canonical  $\alpha$ -amino acids 359  
capillary isoelectric focusing (CIEF) 3–5, 9  
capture and release purification 212  
carbamate linkers 195  
carbohydrates 18  
carbonyl (aldehyde or ketone) 328  
 $N^\alpha$ -carbonyl 169  
carbonyl functionalization 328, 335  
carbonyl moieties 334  
 $^nN$ -carbonyl oxygen 161  
carboxamidomethyl ester (CAM) 266  
carboxyamidomethyl (CAM) protecting group 233  
 $\alpha$ -carboxylate of Boc-Asp(O*t*Bu)-OH 122  
carboxylic acid 127  
3-carboxypropane sulfonamide 215  
catch linker 212  
CCL1 424, 425  
CD spectroscopy 417  
cell nucleus 489  
cell-penetrating peptides (CPPs) 27  
cell signaling 384  
chaotropic agents 229  
chemical analogues 10  
chemical domain of fractalkine (CDF) 423, 424  
chemical ligation methods 2  
chemical ligation reactions 260  
chemical principles 20  
chemical protein synthesis (CPS) 185  
  aminoxy functionalization 335–337  
   $\beta$ -turn mimetics 361–362  
  carbonyl functionalization 328–335  
  *cis-trans* proline isomerization 366–368  
  covalent tethering 371–373  
  discovery, protein folds 373  
  foldamers 375–377  
  glycoproteins 411–413  
  hydrazine functionalization 335–337  
  hydrazone ligation 342–344, 346–348  
  oxidative folding 368–371  
  oxime ligation 337–342, 346–348  
  Pictet-Spengler reaction 344–345  
  protein backbone amides 358–361  
  protein backbone and side-chains 362–366  
  and semisynthesis 515  
  site-specific labelling 373–375  
  TM peptides 456  
  transmembrane (TM) peptides 449  
ChemMatrix 19  
ChemMatrix<sup>®</sup> resin 68  
ChemMatrix PEG Rink-Amide resin 46  
ChemMatrix resin 27  
ChemMatrix Rink amide resin 40, 41  
chemoenzymatic synthesis 413–414  
chemokine CCL2 (MCP-1) 7  
chemokine CXCL14 75  
chemokine interleukin 8 (IL8) 120  
chemokine receptor CXCR1 145  
chemokines 102  
chemoselective KAHA peptide ligation 245  
chemoselective peptide ligation 285  
chemoselective reaction 338, 359  
chimeric anti-protein EGFR nanobody 94  
chiral inactivation 365  
chitin-binding domain (CBD) 494  
2-chlorotriyl-chloride resin 293, 420, 555, 557  
chlorotriyl hydrazide 27  
chlorotriyl PS resin 68  
2-chlorotriyl resin 291  
chromatin immunoprecipitation (ChIP) 497  
Chymotrypsin inhibitor 2 (CI2) 359  
circular/concatenated polypeptide chains 10

- circular dichroism (CD) 105  
 CK2-catalyzed phosphorylations 310  
<sup>14</sup>C-labeled polyamines 339  
 classical alkyl thioester 64  
 classical Fmoc SPPS 68  
 cleavable benzylidene acetal moiety 289  
 2-Cl-(Trt)-Cl resin 91  
 2-Cl-(Trt)-NHNH-Fmoc resin 92  
 2-Cl-(Trt)-NHNH<sub>2</sub> resin 91  
 β-conotoxins 193  
 continuous flow chemistry 18  
 continuous flow solid phase peptide synthesis 18  
 controlled pore glass (CPG) solid support 272  
 convergent covalent condensation 4  
 copper-catalyzed alkyne/azide cycloaddition (CuAAC) 260  
 copper(I) ligands 261  
 CoREST 315  
 covalent C-terminal-linked 327  
 covalent tethering 371, 373  
 crambin 221, 421, 422  
 Crk-II adapter protein 268  
 crosslinked PEG resin 19  
 crude polypeptide product 267  
 crude synthetic peptides 4  
 cryo-electron microscopy (cryo-EM) 111  
 C-terminal alkyl thioester 144, 147  
 C-terminal β-thiolactone 168  
 C-terminal carbonyl 331  
 C-terminal His<sub>6</sub> tag 221  
 C-terminal histidyl thioester 76  
 C-terminal hydrazide 99, 336  
 C-terminal isoleucine-containing peptide 170  
 C-terminally-amidated peptides 266  
 35-mer C-terminal peptide fragment 218  
 C-terminal peptide hydrazides 93, 94  
 C-terminal peptide hydroxylamine (HA) 244  
 C-terminal peptide segments for NCL 217  
 C-terminal peptide thioester 87  
 C-terminal polypeptide hydrazide 93  
 C-terminal proline residues 166  
 C-terminal “safety-catch” linker 193  
 C-terminal salicylaldehyde ester 287, 289, 302  
 C-terminal SECmide 70  
 C-terminal SeEA<sup>off</sup> peptides 68  
 C-terminal selenocysteine (Sec) 63  
 C-terminal Ser thioester 289  
 C-terminal synthetic XH3 (112-135) fragment 130  
 C-terminal thioesters 120, 262, 285  
 C-terminal thio-salicylaldehyde ester 289  
 C-terminal valine-containing peptide 164  
 C-termini of peptides 168  
 C-to-N ligation 294  
 C-to-N peptide ligations 221  
 C-to-N solid-phase chemical ligations 235  
 cubic lipidic phases (CLPs) 443  
 Cu(I)-catalyzed azide-alkyne cycloaddition reaction (CuAAC) 241  
 Curtius rearrangement 88  
 cyclic conotoxins 561, 562  
 cyclic cystine knot (CCK) 565  
 cyclic cystine ladder (CCL) 563  
 cyclic disulfide(diselenide) 66  
 cyclic disulfide bis(2-sulfanylethyl)amido (SEA) polystyrene resin 231  
 cyclic peptides 59, 302, 553  
   classes of 554  
   conotoxins 561–563  
   cyclotides 563, 565–567  
   orbitides 557–558  
   paws-derived peptides (PDPs) 559–560  
   θ-defensins 563, 564  
   synthesis 99, 554–556  
 cyclic proline 161  
 cyclic selenopeptides 472  
 cyclic sulfate 127  
 cyclization linker 214  
 cyclotides 99, 563, 565–567

- Cys-based NCL 173
- Cys-functionalized sepharose solid support 267
- Cys-Gly dipeptide 265
- Cys-masking strategy 262
- Cys- or Met-containing peptides 187
- Cys-peptides 4, 64, 163
- Cys-rich proteins 477
- cysteamine nitrogen 63
- cysteamine scaffold 63
- cysteine (Cys) 61, 463
  - properties 464
- cysteine-aminoethylation assisted
  - chemical ubiquitination (CAACU) strategy 111
- cysteine-cystine redox system 416
- cysteine modifications 311
  - dehydroalanine (DHA) generation 312–313
  - Lys mimics 313–314
  - protein semisynthesis 312
- cysteine side chains 89
- cysteine walk 223
- cysteinyl MUC1peptide hydrazide 248
- cysteinyl-peptide 59, 61, 172, 221
- 19-mer cysteinyl peptide 268
- N*-cysteinyl peptide 167, 178
- cysteinyl peptide H-CSPGYS-NH<sub>2</sub> 176
- cysteinyl prolyl ester (CPE) / imides (CPI) 61
- Cys-to-Sec substitution 466, 475, 476
- Cys-trityl solubilizing tag 197
  
- d**
- DAGK 454–455
- data analysis method 20
- DawsonDbz linker 422
- Dawson's safety-catch strategy 291
- Dbz-linked Asp/Glu residue 197
- θ-defensins 563, 564
- dehydroalanine (DHA) 403, 405, 468, 470
- deiodinases (DIOS) 466
- denaturants 4
- dendrimers 516
- dengue 17
- de novo* design 366
- de novo* proteins 371
- deoxy-D-ribose 5-phosphate aldolase (DERA) POI 93
- L-deoxyribonucleotide triphosphates (L-dNTPs) 113
- deprotected SEA<sup>off</sup> peptide 68
- depsipeptides 187
- Dess-Martin periodinane (DMP) 140
- desulfurization chemistries
  - arginine 139–140
  - asparagine 135–137
  - aspartic acid 122–124, 147–148
  - glutamic acid 124–125, 148–149
  - glutamine 139
  - isoleucine 127–130
  - leucine 133–135, 151
  - lysine 130–133
  - metal-catalyzed hydrogenation reactions 121
  - phenylalanine 125–127, 149–151
  - proline 138–139, 151–153
  - selenocysteine 146–147
  - threonine 140–142
  - tryptophan 144–146
  - valine 142–144
- deubiquitinase (DUB) 109, 111
- deubiquitinating module (DUBm) 498
- 3,4-diaminobenzoic acid (Dbz)
  - derivatized Rink amide resin 291
- 3,4-diaminobenzoic acid (Dbz) linker 193
- diastereomers 27
- 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) 127
- α,α''-dibromo-adipyl(bis)-amide (DBAA) 471
- dichloroacetone (DCA) 334
- 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) 135
- digitoxin 338
- dihydroxylated compound 127
- diisobutylaluminium hydride (DIBAL-H) 143

- N,N*-diisopropylcarbodiimide (DIC) 504  
 diisopropylethylamine (DIEA) 21, 498  
 $\beta$ -diketone 333  
 dimedone 197  
 2,4-dimethoxy-benzaldehyde (Dmb) 439  
*N,N*-dimethylethylenediamine (DMDA)  
 195  
 dimethylformamide (DMF) 20, 189  
 dimethylimidazolidinone (DMI) 20  
 dimethylimidazolidone (DMI) 43  
 dimethyl(methylthio) sulfonium  
 tetrafluoroborate 124  
 dimethyl sulfoxide (DMSO) 187  
 dimethylthiazolidine 441  
 2,4-dinitrophenyl (Dnp) 403  
 2,4-dinitrophenylsulfenyl chloride 145  
 dipeptidyl peptidase IV (DPPIV) 189  
 diphenyldiselenide (DPDS) 153, 172  
 4-(diphenylhydroxymethyl)benzoic acid  
 197  
 direct head-to-tail cyclisation 555  
 direct hydrazinolysis 93  
 direct infusion electrospray ionization  
 mass spectrometry (ESI-MS) 3–5  
 diselenide 148, 153  
 diselenide peptide dimer 175  
 diselenide-selenoester ligation (DSL)  
 146, 153, 181  
 distal Ub-hydrazide 109  
 1,4-disubstituted 1,2,3-triazole products  
 260  
 disulfide bond 400  
 disulfide bond formation 554, 566, 567  
 disulfide-containing proteins 4, 5  
 disulfide cross-linked protein molecule  
 4  
 disulfide rich miniprotein EETI-II 275  
 dithiol(diselenol) 66  
 dithiothreitol (DTT) 73, 146  
 divinylbenzene crosslinked polystyrene  
 resin 27  
 DNA-barcoded nucleosome library (DNL)  
 platform 110  
 L-DNA promoters 113  
 DNA sequencing methods 1
- n*-Dodecyl  $\beta$ -D-maltoside 187  
 dodecylphosphocholine 187  
 double-stranded DNA 490  
 doxorubicin 343  
 D-peptide inhibitors 101  
 drosocin 338  
 DUBs 390, 400–404  
 Duchenne muscular dystrophy 17
- e**
- Ecballium elaterium* trypsin inhibitor II  
 (EETI-II) 365  
*E. coli* strain 317  
 EETI-II analogs 28  
 EETI-II diastereomers 27  
 Eglin C 153  
 electrophilic sulfonylating reagent 122,  
 124  
*d*-enantiomer 517, 518  
 L-enantiomer 517, 518  
 endogenous phospho-amino acids  
 phospho-arginine 544–545  
 phospho-aspartate 543–544  
 phospho-glutamate 543–544  
 phospho-histidine 545–547  
 phospho-serine 541–543  
 phospho-threonine 541–543  
 phospho-tyrosine 541–543  
 pyrophosphorylated serine 547  
 endoplasmic reticulum (ER) 427, 466  
 endoplasmic reticulum-associated  
 degradation (ERAD) 384  
 5-*endo-trig* cyclization 302  
 6-*endo-trig* process 298  
 5-*endo-trig* ring-chain tautomerization  
 287, 298  
 6-*endo-trig* ring-chain tautomerization  
 302  
 enhanced green fluorescent protein  
 (eGFP) 367  
 enzymatic assays 311  
 enzymatic transglycosylation 431  
 enzyme-catalyzed EPL 319  
 enzyme-catalyzed expressed protein  
 ligation 318, 319

- enzyme-catalyzed peptide ligation  
 butelase-1 316–317  
 sortase 314–315  
 subtiligase 317–318  
 trypsiligase 318
- enzyme DapA 259
- Eph tyrosine kinase receptor 193
- epimerization issue 289
- $\gamma$ -epimers 138
- EPO glycoforms 105
- erythro-diastereomer 134
- erythro isomer 122
- erythropoietin (EPO) 105, 127–166, 193,  
 327, 328, 426, 430
- erythro/threo diastereomers 122
- estimated purity 21
- 1-ethyl-3-(3-dimethylaminopropyl)  
 carbodiimide (EDC) 130
- euchromatin 490
- eukaryotic cell development 489
- exenatide 193
- exogenous additive-promoted ligations  
 162
- exogenous additives 167
- exopeptidases 189
- expressed protein ligation (EPL) 107,  
 193, 268, 308, 309, 494, 495  
 development method 308–309  
 N-hydroxysuccinimide-esters 311  
 protein post-translational modifications  
 309–311
- expressed proteins 92
- expression protein ligation (EPL) 92
- f**
- fatty acids 437
- Fc-III mimetic (DCAF) 101
- FDG 340
- $^{18}\text{F}$ -fluorination reactions 338
- first generation automated fast flow  
 peptide synthesis  
 characterization 23–24  
 design 21–23
- $^{18}\text{F}$ -labeling techniques 338
- flow-based peptide synthesizer 18
- flow-based solid phase peptide  
 synthesizer 175
- 9-Fluorenylmethoxycarbonyl (Fmoc-)  
 497
- fluorenylmethoxycarbonyl  
 (Fmoc)-protected amino acids 20
- fluorescence resonance energy transfer  
 (FRET) 403
- fluorophores 10, 373–375
- (4S)-fluoroproline 367
- N-Fmoc-amido-PEG<sub>2</sub>-acid 197
- N-Fmoc amino  
 acyl-N-sulfanylethylaniline unit  
 70
- Fmoc-Arg(Pbf)-OH 43
- Fmoc-Asn(Trt)-OH 43
- Fmoc-Asp-OtBu 143
- Fmoc-based SPPS 90
- Fmoc chemistry 2
- Fmoc-Cys(AcmNHAlloc)-OH 197
- N-Fmoc-1-(4,4-dimethyl-2,6-dioxocyclo-  
 hexylidene)-3-[2-(2-aminoethoxy)  
 ethoxy]-propan-1-ol  
 (Fmoc-Ddae-OH) 197
- Fmoc-Glu(OAll)-OH 215
- Fmoc- $\gamma$ -thiol Pro 138
- Fmoc-His(Trt)-OH 27, 30
- Fmoc-L-Cys(Aapam)-OH (Iris Biotech)  
 197
- Fmoc-NHNH<sub>2</sub> 92
- Fmoc-Pro-OH 47
- Fmoc protected amino acids 24
- Fmoc-protected N-terminal serine 295
- Fmoc-protected proteogenic amino acids  
 43
- Fmoc-SPPS 75, 188, 418–420, 422,  
 424–426, 439, 445, 453, 455, 504,  
 535, 536, 537, 538, 541, 544, 558,  
 568  
 segment synthesis 267
- foldamers 375–377, 522
- folded protein molecule 4
- folded synthetic protein, purification of  
 5



- (2'-formyl-[1,1'-biphenyl]-3-yl)methyl esters 289
- formylglycine 333
- formylglycine generating enzyme (FGE) 332
- Förster resonance energy transfer (FRET) 373, 374
- fourth generation automated fast flow peptide synthesis
- key findings 45
  - solvent effect 45
- <sup>18</sup>F radiolabeling 340
- full length chromosomes 18
- full-length C-terminal peptide segments 212
- full-length GM2-AP protein 75
- full-length hormone 127
- full-length mambalgin-1 toxin 102
- full-length peptide 212, 225
- full length protein 179
- full-length synthetic polypeptide chain 4
- full-length Tat(1-86) protein 135
- fully protected amino acid 122
- functional GM2-AP protein mimics 76
- functionalized cellulose 19
- functional protein molecule 4
- furnished carbamate 130
- g**
- ganglioside 75
- Garner's aldehyde 149
- genes 18
- genetically encoded orthogonal protection and activated ligation (GOPAL) 389, 390
- genetic hypercholesterolemia 17
- genome 1, 18
- Gibbs free energy 360
- GlcNAc-modified membrane protein
- Tim-3 195
- α-globin 398, 400, 401, 405
- globular protein molecule 1
- glutamic acid 89, 124, 148
- glutamine 139
- glutathione/glutathione disulfide redox system 74
- glycine (Gly) 363, 364
- glycine-containing peptide 93
- glycine-dependent amide-forming ligation 302
- glycopeptides 334
- glycopeptide synthesis 412
- glycophorin A (GpA) 443
- glycoprotein assembly 338
- glycoprotein mimetics 10
- glycoprotein modification 335
- glycoprotein oximation 339
- glycoprotein quality control (GQC) 427
- glycoproteins 10, 334, 335
- antifreeze glycoprotein (AFGP) 432–433
  - CCL1 424, 425
  - chemical domain of fractalkine (CDF) 423–424
  - chemical protein synthesis 411–413
  - chemoenzymatic synthesis 413–414
  - crambin 421–422
  - erythropoietin (EPO) 426–430
  - hirudin P6 (HP6) 415–416
  - interleukin 2 (IL-2) 417, 418
  - interleukin 6 (IL-6) 424–426
  - interleukin 8 (IL-8) 425–427
  - interleukin 25 (IL-25) 417–419
  - mucin 1 (MUC1) 419–421
  - saposin D (SapD) 416–417
  - semisynthesis 413
  - α-synuclein 414–415
  - tau protein 422–423
  - trastuzumab 430–432
- glycosylated β-thiol Asn building block 137
- glycosylated cyclic peptides 99
- N-glycosylated IL-6 protein 103
- glycosylation 87
- glycosylation-modified full-length Human interleukin-6 103
- glycosylphosphatidylinositol (GPI) 437
- Gly49-Ile50 junction 359
- (Gly)<sub>3</sub>-labeled barnase 178

- Gly-loaded aminomethyl PS resin 215  
glyoxylic acid 164  
glyoxylyl (Gly) 329  
glyoxylyl moiety 329  
Gly thioesters 142  
GM2 activator protein 75  
GM2-AP protein 75  
GM2 ganglioside activator protein  
(GM2AP) 137  
G-protein coupled receptors (GPCRs)  
437, 447, 456, 457  
granulocyte colony-stimulating factor  
(G-CSF) 185–186  
guanidine 191  
guanidine hydrochloride (GnHCl) 186  
guanidine thiocyanate 187  
guanidinium-hydrochloride (Gdn-HCl)  
442
- h**
- H-AEGSQAKFGX-salicylaldehyde ester  
294  
*Haemophilus Influenzae* DNA ligase 194  
handshake motif 495  
“hard acid” reactivity 286  
“hard base” reactivity 286  
H-Asp(OtBu)-OMe 123  
HATU 557  
2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetram-  
ethyluronium hexafluoro-  
phosphate (HBTU) 20, 30,  
559  
HBV Cp149 protein 197  
HCTU 557  
head-to-tail cyclisation 555, 557, 558  
hemorrhagic fevers 17  
hepatocyte growth factor 1 (HGF1) 272  
hepatocyte growth factor (HGF) 71, 231,  
232, 272  
hepatocyte growth factor/scatter factor  
(HGF/SF) 71  
heterochromatin 490  
hexafluoroisopropanol (HFIP) 187, 197  
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP)  
442  
hexahistidine 221  
 $\beta$ -hexosaminidase A 75  
9H-fluoren-9-ylmethoxycarbonyl (Fmoc)  
554  
highly activated selenophenyl esters 61  
high-performance liquid chromatography  
(HPLC) 211, 495  
high throughput screening (HTS) 401,  
402  
hirudin P6 (HP6) 415  
His<sub>6</sub>-labelled MUC1 thioester 248  
His<sub>6</sub>-Ni(II) interaction 240  
His<sub>6</sub> tag  
and hydrazide tags for sequential  
N-to-C capture and release  
225–227  
and hydrazide tags for sequential n-to-c  
capture and release 223–225  
immobilization for assembly of proteins  
on microtiter plates 222–223  
immobilization for C-to-N assembly of  
crambin 221–222  
reversible HIS<sub>6</sub>-based capture tags 220  
histidine degradation studies 30  
histidine monomer Fmoc-His(Trt)-OH  
20  
histidine racemization studies 33  
histone proteins 393  
histone synthesis  
acetylation 499–502  
erasers 491  
methylation 502–505  
native chemical ligation (NCL)  
492–493  
octamer and nucleosome core particle  
assembly 494–496  
phosphorylation 497–499  
post-translational modifications  
490–492  
proteins 489–490  
readers 491  
sumoylated histones 505–506,  
505–507  
writers 491  
histone tails 490, 491

- HIV entry-associated chemokine receptor  
CXCR4 123
- HIV-1 protease 193
- H4K16ac 98
- H3K4me3 98
- Hmb(Ac) auxiliary group 298
- Hmb(Ac)Gly96-containing peptide 298
- Hmb linker 194
- HMGA1a protein 298
- homogeneously modified CXCR4 (1-38)  
peptide 123
- homogeneous phosphorylated p62 105
- homogeneous synthetic protein molecule  
7
- homoserine isoacyl bond intermediate  
189
- HPLC-free preparation  
of C-terminal peptide segments for  
NCL 217  
of N-terminal peptide segments for  
NCL 213
- HPLC-free synthesis, of proteins using the  
KAHA LIGATION 245–246
- H-SPKALTFG-OH 294
- human anaphylatoxin C5a 229, 231
- human cytomegalovirus protein UL22A  
151
- human erythropoietin segment (hEPO)  
195
- human group V secretory phospholipase  
A<sub>2</sub> (GV-PLA<sub>2</sub>) 266
- human growth hormone (hGH) 469
- human interleukin-6 (IL-6) 103
- human parathyroid hormone (hPTH)  
143, 179
- human thyroid-stimulating hormone  
(hTSH)  $\beta$ -subunit 197
- Hyalomin 3 (Hya3) 148
- 2-hydroxy-nitrobenzyl (Hnb) 446
- hydrazide-based native chemical ligation  
101
- hydrazide functionalization 335, 337
- hydrazide resin 91
- hydrazide tags for sequential *N*-to-*C*  
capture and release 225–227
- hydrazine 212
- hydrazine functionalization 337
- hydrazone formation  
immobilization for assembly of proteins  
on microtiter plates 239–241  
immobilization for *N*-to-*C* solid-phase  
peptide ligations using a protected  
alkyne 241, 242–243  
immobilization for *N*-to-*C* solid-phase  
peptide ligations using a sea group  
242–243, 243–244  
reversible hydrazone-based capture tags  
238–239
- hydrazone ligation 342, 344, 346, 348
- hydrogen bonding 359, 520
- hydrogenolysis 90
- hydrophobic membrane 438  
proteins 187
- hydrophobic peptides 438, 441, 442, 445,  
450, 453, 454
- $\beta$ -hydroxyamic acids 189
- 1,2-hydroxyamine 287
- 1,2-hydroxyamine bifunctionality 287
- 4-hydroxybenzoate 91
- hydroxybenzotriazine (HOObt)-mediated  
coupling 137
- 1-hydroxybenzotriazole (HOBT) 130, 195
- $\gamma$ -hydroxy Gln variant 139
- $\beta$ -hydroxy Leu 133
- 1-hydroxyl-1H-1,2,3-triazole-4-carboxylate  
(HOct) 90
- 5-R hydroxylysine 133
- 4-hydroxy Lys precursor 130
- $\beta$ -hydroxy Lys variant 133
- 2-hydroxy-3-mercaptopropionic acid  
194
- 2-hydroxy-4-methoxybenzaldehyde  
(Hmb) 439
- N*-(2-hydroxy-4-methoxy benzyl) (Hmb)  
194
- (2-hydroxy-4-methoxybenzyl) auxiliary  
group 298
- 2-hydroxy-4-methoxy-5-methylsulfinyl  
benzyl (Hmsb) 441

- 4-hydroxymethylbenzoic acid (HMBA) 193
- 4-(hydroxymethyl)phenoxyacetic linker (HMPA) 266
- 4-(hydroxymethyl)phenoxypropionic linker (HMPP) 266
- hydroxymethyl salicylaldehyde 302
- N*-hydroxy moieties 302
- N*-(2-hydroxy-5-nitrobenzyl)-cysteinamide (*N*-Hnb) group 63
- $\beta$ -hydroxyphenylalanine variant 125
- hydroxy-phosphorylated amino acids, into peptides and proteins 534, 537
- trans*- $\beta$ -hydroxy Pro derivative 138
- trans*- $\gamma$ -hydroxyproline 151
- N*-hydroxysuccinimide (NHS) esters 311
- hydroxytrityl ChemMatrix<sup>®</sup> resin 68
- hydroscopic amino acid solutions 26
- i**
- imidazole 167
- groups 191
- phosphonate reagent 541
- imine ligation 327–329
- immobilization for assembly of proteins on microtiter plates 222–223, 239–241
- immobilization for *C*-to-*N* solid-phase chemical ligations 233–237
- immobilization for *N*-to-*C* solid-phase chemical ligations 227–233
- immobilization for *N*-to-*C* solid-phase peptide ligations using a protected alkyne 242–243
- immobilization for *N*-to-*C* solid-phase peptide ligations using a sea group 243–244
- immobilized metal ion affinity chromatography (IMAC) 221
- immobilized peptide segment 212, 214
- immunoglobulin G (IgG) 101, 365, 430–431
- immunoglobulin variable (IgV) domain of PD-L1 (D-PD-L1IgV) 101
- inactive cyclic diselenide 72–73
- influenza BM<sub>2</sub> peptide 197
- influenza BM<sub>2</sub> proton channel 194
- inorganic matrixes 276–277
- in situ-formed heterobicyclo[2.2.1]septane structure 169
- insulin-degrading enzyme (IDE) 369
- insulin-like growth factor 1 (IGF-1) 364
- intein 92–93, 103, 130, 308–310, 317, 319, 375, 414, 422, 425, 457, 467, 474, 494–495, 505
- intein-mediated protein splicing 61
- interferon-induced transmembrane protein 3 (IFITM3) 453
- interleukin 2 (IL-2) 417, 418
- interleukin 6 (IL-6) 103, 104, 424–426
- interleukin 8 (IL-8) 120, 425–427, 475, 520, 523
- interleukin 25 (IL-25) 294, 296, 417–419
- intermediate SEA<sup>off</sup> peptide 72
- intermediate SEA<sup>on</sup> species 270
- intermolecular O $\rightarrow$ S peptidyl transfer 170
- internal Alloc-protected Aoa-MUC1 segment 237
- internally activated peptide Nbz derivatives 179
- intra- and inter-molecular ligation reactions 317
- intramolecular iodocyclization 124
- intramolecular *S,N*-acyl shift 87
- intrinsically disordered proteins (IDPs) 7, 357, 377
- iodoacetic allylester 215
- iodoacetyl-*N*-acetylglucosamine 78
- cis*- $\gamma$ -iodoproline 151
- ion channels 1, 101, 112, 365, 446, 450, 453, 456, 561
- ionizable picolyl ester group 212
- irreversible *S*-to-*N* acyl transfer 285
- isoacyl  $\alpha$ -amine 189
- isoacyl dipeptides 188, 198
- isoacyl peptides 187, 189
- isocyanate byproducts 187
- isoleucine (Ile) 127, 129, 130, 161, 365, 367, 495

- isonicotinyloxycarbonyl (iNoc) 195, 417  
 isopeptide bond 383, 384, 387, 389, 390, 393, 395, 401, 403, 404  
 isopeptide chemical ligation (ICL) 390, 392, 395, 399–401  
 isopeptide ligation 387, 389, 391  
 isopeptide-linked Ub isomer 109  
 isopropyl bromide 151  
 isoxazolidine tag 245, 246
- j**
- Jones oxidation 334  
 JR-10mer 41, 43, 45, 49
- k**
- kaliotoxin 164  
 K<sup>+</sup> channel protein Kir5.1 112  
 KcsA K<sup>+</sup> channel 193  
 keratins 1  
 $\alpha$ -ketoacid-hydroxylamine (KAHA)  
   ligation 453  
 ketoacid-hydroxylamine (KAHA) ligation  
   strategy 187, 189  
 ketoamide 329, 330  
 ketones 227, 234, 250, 266, 270, 328–331, 333–335, 337, 342–343, 348, 413  
 ketoproline 333–334  
 K19, K48 bi-acetylated Atg3 protein 105, 107  
 K27/K29/K33-linkage selective  
   deubiquitinase OTUD2 109  
 K27-linkage isopeptide bond 108  
 K27-linked diUb 108, 109  
 K27-linked tetra-Ub and  
   K11/K48-branched tri-, tetra-,  
   penta-, and hexa-Ubs 109  
 K27-linked triUb 109  
 K27-linked ubiquitin chains 108  
 K27-modified proximal Ub 109  
 Knauer pumps 24, 26  
 Knorr pyrazole synthesis 94
- l**
- LabVIEW software package 38, 39  
 ladder sequencing 4  
 latent acyl donor 72, 285–287  
 latent thioesters 59, 61, 66–67, 75, 79, 114, 139, 231, 270, 417  
 LC/MS purity of peptides 21  
 leucine 133–135, 151, 366, 495  
 Leu thioesters 142  
 levulinic acid 227, 266, 270, 334  
 ligation(s) 60, 64, 71, 76, 94, 142, 146, 161–181, 189, 212–213, 217, 221, 227–238, 242–246, 261–266, 268–270, 273, 294, 296, 314–318, 346–348, 470, 474  
 ligation reactions 53, 59, 61, 63, 64, 67, 74, 96, 103, 105, 125, 145, 169, 172–173, 187, 194, 245, 259, 260, 276, 278, 317, 443, 453–457, 492, 516–517  
 linear *N*-Cys-tetrapeptide hydrazide  
   precursor 99  
 $\alpha$ 2,6-linked sialylglycopeptide (SGP) 431  
 lipoic acid ligase (LpIA) 332, 337  
 $\beta$ -lipotropin ( $\beta$ -LPH) analogue 169  
 lispro insulin 342  
 lithium enolate 122, 124, 147, 149  
 lithium hexamethyldisilazide (LiHMDS)  
   122  
 LL-37 48, 51  
 low molecular weight peptidic products  
   27  
 lumbricin-1 175, 179, 181  
 lysine 108, 130–133, 247, 289, 329, 334, 338, 443, 445, 449, 492, 500, 504–505, 533  
 lysine acetylation 492
- m**
- maltose-binding protein (MBP) 474  
 mambalgin-1 101, 102  
*m*-chloroperbenzoic acid (mCPBA) 142  
 mechanical principle 20  
 12-membered cyclic tetrapeptide 99  
 13-membered thiolactone intermediate  
   99  
 membrane protein 112, 438  
   dysfunction 112

- 1,2-mercaptoamine bifunctionality 285
- $\delta$ -mercaptolysine 389, 390, 392, 393, 395, 398, 400
- $\gamma$ -mercaptolysine 389, 390
- 4-mercaptophenylacetic acid (MPAA) 72, 130, 162, 261, 399–400, 400
- trans*-4-mercaptoproline derivative 169
- 4-mercaptoprolyl thioester-based ligation 169
- 3-mercaptopropionic acid (MPA) 243, 387
  - derived thioester 71, 164
- mercaptopropionic acid (MPA) 232
- $\beta$ -mercapto amides 268
- 35-mer C-terminal peptide fragment 218
- mercury(II) acetate 263
- metagenome 1
- metal-free desulfurization approach 169, 274
- metal-free dethiolation (MFD) 492
- methanol (MeOH) 185
- methionine 121
- methionine-containing peptides 215
- methionine residues 215
- 7-methoxy-coumarin-4-acetic acid (MCA) 403
- 2-methoxy-4-methylsulfinylbenzyl alcohol 193
- 4-methoxy-5-nitrosalicylaldehyde 194
- methylated histone H3 504
- methylation 393, 502, 505
- N*-methylation 373, 520
- $\alpha$ -methylcysteine 61
- methyl ester 127
- (2'-formyl-[1,1'-biphenyl]-3-yl)methyl esters 289
- 5-methyl isoxazole-carboxamide (MICA) 130
- methyl methanethiosulfonate (MMTS) 133
- methylsulfonylethoxycarbonyl (MSC) 262
- methyl/*t*-butyl methanethiosulfonate (tBMTS) 133
- methylthiocarbonyl-aziridine (MTCA) 313
- methyl thioglycolate (MTG) 162
- MET tyrosine kinase receptor 71
- Michael acceptor 132
- microfluidics-promoted NCL 175
- $\beta$ 2-microglobulin ( $\beta$ 2m) 362, 363, 367, 371
- microtiter plates 222–223
- mirror-image biological systems 112
- mirror-image biomacromolecules 113
- mirror-image protein(s) 10, 362, 363
- misfolded polypeptide chains 4
- 7–12  $\mu$ m Porex UHMWPE membrane 46
- model peptides 39
- 46-mer model protein 221
- modified N terminal peptide hydrazide 107
- modified nucleosomes
  - cysteine-aminoethylation assisted chemical ubiquitination strategy 111
  - DNA-barcoded nucleosome library (DNL) platform 110
  - ubiquitylated histones 111
- modified RNA 17
- molecular dynamics (MD) simulations 358, 361, 364
- molecular feature extraction (MFE) 21, 27
- mono- and diubiquitin (Ub) 111
- monoclonal antibodies 339
- monoglycosylated prolyl thioester 78
- monoisotopic mass 5
- monomers 327
- monoubiquitinated H2B 396
- monoubiquitinated proteins 393, 397
- mouse thioredoxin reductase 3 (Mtr3) 474
- MPAA-derived thioester 178
- MPA-thioester 72
- 7–12  $\mu$ m Porex UHMWPE membrane 46
- Msz (p-(methylsulfinyl)benzyloxy-carbonyl) group 295
- Msz-Ser(*t*Bu)-OH 295

- mucin 1 (MUC1) 419, 421  
 MUC1 protein 243  
 9 MUC1 proteins 225  
 multi-dimensional NMR fingerprinting  
     5  
 multiple acidic sialyloligosaccharides  
     105
- n**
- native amide-bond metathesis reactions  
     63  
 native chemical ligation (NCL) 59, 120,  
     162, 185, 211, 259, 308, 319, 372,  
     387, 412, 414–416, 424, 442, 445,  
     446, 449, 450, 469, 470, 473, 474  
     chemoselective approach 555  
     development of 516, 517  
     histone synthesis 492–494, 493  
 native NK1 74  
 native triphosphorylated tau peptide 247  
 natural N-terminal thioester 103  
 natural peptide bond 308  
 natural RNA 17  
 natural Sec-containing proteins 173  
 neopentyl (nP) ester 151  
 Ni(II)-loaded microtiter plate 222  
 N-im Boc-protection 24  
 N-im trityl-protected histidine 24  
 Ni-NTA agarose resin 225  
<sup>15</sup>N-isotope-labeling (SGI) 423  
 nitro alcohol 131  
*p*-nitrophenol (ONp) derivatives 227  
*p*-nitrophenol-derived ester 170  
 4-nitrophenyl chloroformate 291  
 nitrophenylester-based ligation 170  
*p*-nitrophenyl ester protocol 170  
*p*-nitrophenylsulfonyl (Nosyl) chloride  
     134  
 6-nitroveratryloxycarbonyl (Nvoc) group  
     274  
 nitroveratryloxycarbonyl (NVOC)  
     photo-cleavable amino protecting  
     group 189  
 NK1-B polypeptide 74  
 NK1-B protein 75
- NK1 protein 71  
 [Nle<sup>8,18</sup>]hPTH 179  
*N*-linked glycosylation 411  
*N*-(2-mercaptoethoxy)amide scaffold  
     61  
*N*-methylpyrrolidone (NMP) 20  
*N*-monomethyltrityl (Mmt) 215  
 NMR spectroscopy 358, 361, 371, 423  
*N,N*-dimethyl barbituric acid (NDMBA)  
     237, 264  
*N,N*-dimethylethylenediamine (DMDA)  
     195  
*N, O*-acetal intermediate 302  
*N,O*-benzylidene acetal 287  
*N,O*-benzylidene acetal ligation product  
     289  
*N,O*-benzylidene acetal moiety 287  
 nonapeptide PPAHGVSTA 265  
 non-canonical amino acid 366, 367, 374,  
     375  
 non-canonical phosphorylation 538  
 non-coded amino acids 10  
 non-enzymatic ubiquitination  
     isopeptide ligation 387, 391  
     Ub building blocks 387  
 non-ionic detergents 187  
 nonproteinogenic amino acid canaline  
     198  
*p*-NO<sub>2</sub>-phenol 170  
*N*-or C-terminal solubilizing “tails,”  
     192–194  
*N,S*-acyl transfer systems 61  
*N,S*-and *N,Se*-acyl transfer devices  
     biotinylated analogue of the HGF/SF  
     NK1 domain 71–75  
     chemical protein synthesis 61  
     cyclic peptides 59  
     cysteinyl peptide 59  
     general presentation 61  
     GM2 activator protein 75–79  
     latent thioesters 59  
     native chemical ligation 59  
     peptide thioester 59  
     protein scaffolds 59  
     relative reactivity 63

- N,S*- and *N,Se*-acyl transfer devices  
 (contd.)  
     SEA and SeEA peptides 68–70  
     statistical overview 64–68  
*N,S*- and *N,Se*-acyl transfer devicesSEA  
     and SeEA peptides 70  
*N*-selenocysteiny peptide 174  
*N*-substituted cysteamine 61  
*N*-substituted glycine residues 343  
*N*-(2-sulfanylethyl)amide motif 61  
*N*-sulfanylethylaminoxybutyramide  
     (SEAoxy) 63  
*N*-sulfanylethylanilide (SEAlide) 63  
*N*-(2-sulfanylethyl)cysteine 63  
*N*-terminal aldehydes or ketones 330  
*N*-terminal amino acid 285  
*N*-terminal aminoxy group 237  
*N*-terminal aminoxyacetic acid (Aoa)  
     237, 266  
*N*-terminal bifunctional amino acids 286  
*N*-terminal cysteine 99, 221, 262, 285  
*N*-terminal cysteine residue 120  
*N*-terminal cysteine thiazolidine (Thz)  
     76  
*N*-terminal diselenide 147  
*N*-terminal g-thiol Glu residue 124  
*N*-terminal homoserine 302  
*N*-terminal ketone 330–331  
*N*-terminally cysteinyl peptide segments  
     220  
*N*-terminal MASSRVDGGRSDLIEGRC  
     appendage 268  
*N*-terminal model peptide 294  
*N*-terminal oxazolidinone 227  
*N*-terminal peptide  $\alpha$ -ketoacid (KA) 245  
*N*-terminal peptide segments 213, 237  
*N*-terminal peptide thioester 96  
*N*-terminal peptide thioester fragments  
     222  
*N*-terminal serine 329  
*N*-terminal Ser/Thr 287  
*N*-terminal Ser/Thr residue 287  
*N*-terminal (Gly)<sub>3</sub>-tagged peptide 178  
*N*-terminal triphosphorylated tau  
     segment 247  
*N*-to-*C* ligation 296  
 nucleation 362  
 $\alpha$ -nucleophiles 335  
 nucleosome core particle assembly 494,  
     496  
**O**  
*o*-amino(methyl)aniline (MeDbz) linker  
     193  
 octamer 494, 496  
 Octyl- $\beta$ -glucoside 187  
*O*-glycoproteins 272  
*O*-glycosylated serine residues 272  
*O*-glycosylated variants 193  
*O*-glycosylation 411, 415, 419, 427  
 oligonucleotide (ODN) 18, 341  
 oligosaccharide structure 105  
*O*-linked  $\beta$ -*N*-acetyl-glucosamine  
     (*O*-GlcNAc) 310  
*O*-linked glycopeptide 334  
*O*-mesitylenesulfonylhydroxylamine  
     312  
*O*-methylhydroxylamine 218  
 one-pot ligation 96  
 one-pot sequential  
     NCL/SEAlide-mediated ligation  
     process 75  
 one-pot Ser/Thr ligation 296  
*O*-phosphoseryl-tRNA<sup>[Ser]<sup>Sec</sup>(pSer-  
     tRNA<sup>[Ser]<sup>Sec</sup>) 464  
 orbitides 557, 558  
 organic solvents 442, 449  
*ortho*-nitrobenzyl linker 196  
*O*-to *N*-acyl shift 189  
     kinetics 189  
*O*-to-*N* acyl transfer 287, 298, 302  
 OTUD2 mutagenesis assays 109  
 1,2,5-oxadiazinane ring 302  
 oxazolidine 149, 151, 287  
*trans*-oxazolidinone 125  
 oxazolidinone intermediate 125  
 oxazolidone-based strategy 217  
 oxazolones 289  
 oxidative folding 368, 370, 371  
 oxidizable amino acids 293</sup></sup>



- oximation 337
  - oxime 212
  - oxime bond 337
    - formation 402
  - oxime formation
    - C-to-N solid-phase chemical ligations 237–238
    - immobilization for C-to-N solid-phase chemical ligations 233–237
    - immobilization for N-to-C solid-phase chemical ligations 227, 230–233
    - reversible oxime-based capture tags 227
  - oxime ligation 337, 338, 342, 346, 348
  - oxo-esters 170
- p**
- 1-palmitoyl-2-oleoyl-3-glycero-phosphatidylcholine 187
  - partially protected ribonuclease 90, T1
  - paws-derived peptides (PDPs) 554, 559, 560
  - Pd(0)-catalyzed deprotection 214
  - PD-L1-binding D-peptide molecules 101
  - PEG 338
  - PEGA1900 resin 272
  - PEG-based synthetic polymers 276
  - PEG-polyacrylamide PEGA resins 276
  - PEG-poly(oxetane)copolymer 276
  - pentafluorophenyl (Pfp) ester 137
  - 36-mer peptide 178
  - 42-mer peptide 91
  - 62-mer peptide 181
  - peptide aggregation 185
  - peptide azide 88
  - peptide bond formation 327
  - peptide-CONHNH<sub>2</sub> 4
  - peptide C-terminal 2-formylbenzyl ester 289
  - peptide C-terminal glycolaldehyde esters 286
  - peptide cyclisation 553
  - peptide hydrazides
    - activation in TFA 94–95
  - acyl azide-based solution phase peptide synthesis 89–90
  - 2-Cl-(Trt)-Cl resin 91–92
  - convergent ligation 96
  - conversion to peptide azide 88
  - cyclic peptide synthesis 99
  - DCAF 101
  - D-peptide inhibitors screening 101
  - erythropoietin (EPO) 105
  - expressed proteins 92–93
  - glycosylation-modified full-length Human interleukin-6 103
  - homogeneous phosphorylated p62 105
  - isopeptide-linked Ub isomer 109
  - isopeptide-linked Ub 76-mer 109
  - K19, K48 bi-acetylated Atg3 protein 105–107
  - K27-linked ubiquitin chains 108–109
  - Knorr pyrazole synthesis 94
  - ligation sites 95
  - membrane proteins 112
  - mirror-image biological systems 112–113
  - modified nucleosomes 110–111
  - native chemical ligation 90
  - N-to-C sequential ligation 96
  - one-pot ligation 96–99
  - peptide toxins 101–102
  - sortase-mediated hydrazide generation 93–94
  - transesterification of acyl azide 90
  - two-photon activated chemokine CCL5 103
  - peptide insolubility 185
  - peptide ligations
    - exogenous additive-promoted ligations 162–167
    - internal activation strategy 169–170
    - microfluidics-promoted NCL 175
    - oxo-esters 170
    - reactive thioesters 167–168
    - representative applications 178–181
    - selenoesters 170–175
  - peptide prolyl hydrazide 167

- peptide prolyl selenoester 172, 174
- peptides 18
- 30-mer peptides 46
- peptide salicylaldehyde esters 289, 291, 293, 294, 296
  - via Boc-SPPS 291
- peptide seleno-salicylaldehyde esters 289
- peptide sequence 559
- peptide solubility
  - isoacyl peptides 187–191
  - semipermanent solubilizing tags 191–198
  - solvent manipulation 185–187
- peptide therapeutic teriparatide 124
- peptide thiocarboxylate segments 268
- peptide thioesters 4, 59, 75, 91, 99, 189, 213, 309
- peptide thio-salicylaldehyde esters 289
- peptide toxins 101
- peptidic Xaa-Ser/Thr linkage 287
- peptidomimetic triazole ligation (PTL) 260
  - strategy 270
- peptidyl alkyl thioesters 167, 179
- peptidyl azide-based ligation protocol 178
- peptidyl azides 166
- peptidyl C-termini 163
- peptidyl hydrazines 167
- peptidyl impurities 214
- peptidyl MPA-thioester 72
- peptidyl *N*-alkylcysteine 61
- peptidyl Pen-Nbz 179
- peptidyl *p*-nitrophenyl ester 170
- peptidyl prolylselenoester 172, 175
- peptidyl prolyl thioesters 163, 169
- peptidyl selenoester 173
- peptidyl thiazolidine thioester 164
- peptidyl thioester intermediate 164
- peptidyl thioesters 161, 169, 172
- peptidyl valinyl  $\alpha$ -thiophenolester 167
- peptidyl valinyl thioesters 163, 169
- peptoid oligomer 297
- PF4 327
- Pfp-active ester 137
- L-Phe methyl ester 125
- phenylacetamido (PAM)-substituted
  - phenylalanine linker 193
- phenylalanine 125, 149
- 9-(9-phenylfluorenyl) (PhFl)
  - functionalized amino acid 143
- phenylisopropyl ester 137
- 2-phenyl-isopropyl (PhiPr)-ester 215
- phenylisopropyl trichloroacetimidate 135
- phenylselenoester 174
- phospho-arginine (pArg) 537, 538, 544, 545
- phospho-aspartate 543, 544
- phospho-cytosine (pCys) 539, 541
- phospho-glutamate 543, 544
- phospho-histidine (pHis) 538, 539, 545, 547
- phosphohistidine phosphatase 1 (PHPT1) 470
- phospholamban 447, 449, 450
- phospho-lysine (pLys) 539
- phosphonates 541–543
- phosphonodifluoromethyl alanine (Pfa) 542
- phosphono-difluoromethylene alanine (PFA) 310
- phosphonomethyl alanine (Pma) 542
- phosphoramidates 533, 537, 538, 543
- phosphorodiamidate morpholino oligomers 17
- phosphorothioates 533, 539
- phosphorylated histone H2A 499
- phosphorylated nucleophilic amino acids
  - into peptides and proteins
- phosphoarginine (pArg) 537–538
- phosphocytosine (pCys) 539–541
- phosphohistidine (pHis) 538–539
- phospholysine (pLys) 539
- pyrophosphorylation (PTM) 541
- serine and threonine 541
- phosphorylation 393, 395, 398, 497, 499
- phosphorylation assays 369
- phospho-serine 541, 543

- phosphoseryl-tRNAkinase (PSTK) 464  
 phospho-threonine 541, 543  
 phospho-tyrosine 541, 543  
 photocleavable biotin-based purification tag 246–247  
 photocleavable His6-based purification tag 247–249  
 picolyl esters (OPic) 195  
 Pictet-Spengler reaction 329, 344, 345  
 piperidine 21, 195  
 plant homeodomain (PHD) 503  
*p*-methoxybenzyl (PMB)  
   diselenide 147  
   thiol 135  
*p*-nitrophenol (ONp) derivatives 229  
*p*-nitrophenol-derived ester 170  
*p*-nitrophenyl ester protocol 170  
*p*-nitrophenylsulfonfyl (Nosyl) chloride 134  
*p*-NO<sub>2</sub>-phenol 170  
 POI-sortase thioester intermediate 93  
 polar PEG-based polymers 276  
 polyethylene glycol (PEG) 191  
   functionalized polystyrene resin 19  
 polypeptide chain 358  
   backbone 10  
 polystyrene 19  
   solid supports 18  
 polyubiquitination 383  
 positively charged amino acids 192  
 positively charged moieties 191  
 positron emission tomography (PET) 338  
 post-ligations solid-supported transformations  
   biochemical transformations 275  
   chemical transformations 274  
 posttranslational phosphorylations 534  
 post-translational modifications (PTMs) 213, 309, 383  
 potassium selenocyanate 149  
 potassium thioacetate yielded g-thiol Lys variant 130  
 potassium toluene thiosulfonate 122  
 premade peptidyl thioesters 164  
 prenyl groups 437  
 preparative HPLC 8  
 PreSciss linker 268  
 primary alcohol 149  
 Proliferating Cell Nuclear Antigen (PCNA) 311  
 Proline 138, 151  
*cis-trans* proline isomerization 366–368  
 proline-rich peptide submaxillary gland androgen regulated protein 3B (SMR3B) 153  
 proline-rich polypeptides 175  
 prolyl ester carbonyl 161  
 prolyl SEA peptide 166  
 prolyl thioester 78, 164, 166, 169  
 propargyloxycarbonyl (Proc) 196  
 17-mer propeptide sequence 263  
 proteasome 400  
 protein 411  
   aggregation 357  
   conjugates 344  
   design 376  
   diastereomers 10  
   function 357, 364, 377, 522  
   mimicry 522  
   misfolding 357  
   polypeptide chain 1  
   scaffolds 59  
   semisynthesis 307, 311  
   splicing 308  
   stability 359  
   structure 358, 369, 373, 377  
   thioester 317, 319  
   ubiquitination 108  
 protein backbone  
   alteration 521  
   amides 358, 361  
   side-chains 362, 366  
 protein farnesyltransferase (PFTase) 332  
 protein folding 357–359, 465  
   GSeSeG 478  
   selenium 475–478  
 protein mimetics, backbone engineering 522–525

- protein molecules
    - atomic structure 7
    - characterization of 8
    - chemical synthesis 2
    - covalent structure 9
    - defined folded structure 7
    - function of 1
    - homogeneity 7
  - protein of interest (POI) 92
  - proteinogenic amino acids 121, 266
  - protein synthesis
    - “click” chemistry 242–244
    - His6 tag 221–222
    - KAHA ligation 244–246
    - oxime formation 225–238
    - photocleavable tags 246–249
    - via hydrazone formation 238–241
  - proton donor 347
  - pseudoproline dipeptides 188
  - PTMs 490, 491, 494–497, 500, 506
  - PylRS-tRNACUAPyl system 93
  - pyrazole 546
  - pyridinium dichromate (PDC) 127, 149
  - pyridoxal 5'-phosphate (PLP) 329
  - pyridylmethoxycarbonyl (iNoc)-protected
    - isoacyl peptides 189
  - pyroGlu-ADan 189
  - pyroglutamate aminopeptidase 189
  - pyrophosphorylated serine 547
  - pyrophosphorylation (PTM) 541
  - pyruvic acid 334
- q**
- quasiracemic protein 518, 519
- r**
- racemic protein 517–519
    - crystallography 7
  - radiometric assays 339
  - radiosyntheses 338
  - RANTES 327, 338
  - reactive peptidyl  $\alpha$ thiophenylesters 167
  - reactive peptidyl thioester SEAE 176
  - reactive thioesters 167
  - recombinant C-terminal protein
    - hydrazine 93
  - recombinant expression 358
  - recombinant polypeptide
    - $\alpha$ -N-acetyl-galactosaminyl transferase 1 (pp-GalNAc-T1) 275
  - redox-controlled latent thio-and
    - selenoesters 66
  - redox homeostasis 465
  - re-immobilization of the C-terminal
    - fragment 266
  - removable-backbone modification (RBM)
    - strategy 112, 194, 298, 446
  - Replication Protein A (RPA) 311
  - 180-residue biotinylated NK1 domain
    - (NK1-B) 231, 232
  - 86-residue HIV regulatory protein TAT 135
  - 118-residue human group V secretory
    - phospholipase A<sub>2</sub> (GV-PLA<sub>2</sub>) protein 233
  - 136-residue (15 kDa) polypeptide 243
  - residue polypeptides 101
  - 84-residue protein 143
  - 66-residue protein CssII 96
  - 71-residue target protein 147
  - 160-residue triazole-derivative 241
  - reverse-phase high performance liquid
    - chromatography (RP-HPLC) 185, 416, 494, 496
  - reverse polarity protection 195
  - reversible backbone modification 194
  - reversible HIS6-based capture tags 220
  - reversible hydrazinyl tag 238
  - reversible hydrazone-based capture tags
    - 238
  - reversible oxime-based capture tags 227
  - reversible transthioesterification 285
  - R-Garner's aldehyde 127
  - 5-R hydroxylysine 133
  - ribonuclease T1 89
  - ribosomal protein S25 96
  - ribosomal RNA 494
  - ring-chain tautomerization 298

- Rink amide linker 27, 267  
 Rink amide-PEGA solid support 265  
 Rink linker cleavage 265  
 RiPPs 554  
 RP-HPLC 559, 563
- S**
- safety catch acid-labile linker (SCAL)  
 266
- salicylaldehyde derivative 194  
 salicylaldehyde dimethyl acetal 291  
 saposin D (SapD) 416  
 Schiff base 346  
 SEA and SeEA peptides 68, 70  
 SEA ChemMatrix<sup>r</sup> resin 68  
 SEALide chemistry for protein total  
 synthesis 75  
 SEALide-derived thioester 67  
 SEALide-mediated one-pot process 75  
 SEALide peptides 70  
 SEALide system 66, 67  
 SEAoff peptides 68  
 SEAoff/SEALide latent thioesters 67  
 SEAoff/SeEAoff latent thio- or selenoester  
 precursors 71  
 SEAon peptide 74, 176  
 SEA polystyrene resin (SEAPS) 68  
 SEA/SeEA and SEALide-based ligations  
 64  
 SEA/SeEA system 66  
 SEA trityl solid supports 68  
 Sec-based ligation 173  
 Sec biosynthesis (SPS) 465  
 second generation automated fast flow  
 peptide synthesis  
 amino acid stocks design 26  
 characterization and use of 26  
 key findings 24  
 pump design 24, 26  
 valve design 24  
 Seebeck group 537  
 segment D delivered SeEAoff peptide 74  
 selenazolidine (Sez) 470, 471, 474  
 selenium, tool for protein folding  
 475–478
- selenoamino acid-derived peptides 174  
 $\beta$ -seleno Asp variant 147  
 selenocysteine (Sec) 63, 64, 146, 173,  
 368–370, 463, 472  
 properties 464  
 reactive handling 469–473  
 selenocysteine insertion sequence (SECIS)  
 463  
 selenoester 64, 66, 148, 170  
 selenoester/diselenide-based ligation  
 174  
 seleno-insulin 370  
 selenol-based ligation 173  
 selenol ligation auxiliary 153  
 SELENON gene 466  
 $\beta$ -seleno Phe 149  
 selenophenol 61, 172  
 selenophosphate synthetase 2 (SPS2)  
 466  
*trans*- $\gamma$ -selenoproline 175  
 selenopropyl peptides 173  
 selenoprotein M (SELENOM) 470  
 selenoprotein P (SELENOP) 466  
 selenoproteins 463–466  
 expression 466–469  
 synthesis and semi-synthesis of  
 473–475  
 selenoprotein S (SELENOS) 466  
 selenoproteinselenophosphate synthetase  
 2 (SPS2) 464  
 selenoprotein W (SELENOW) 466  
 seleno-salicylaldehyde esters 289  
 selenylated amino acid 149  
 selenylating reagent 147  
 self-purification effect 274  
 self-purified peptide thioesters 239  
 semicarbazone 293  
 semipermanent “helping hand” linker  
 197  
 semipermanent solubilizing tags  
 building blocks 195  
 extendable side-chain-based  
 solubilizing tags 195  
 N- or C-terminal solubilizing “tails”  
 192  
 reversible backbone modification 194

- semisynthesis, glycoproteins 413
- semi-synthesized diacetylated Atg3 107
- semisynthetic H3 proteins 315
- sequential N-to-C ligation 96
- Ser63-Gln106 298
- serine 153, 541
- serine/threonine ligation 287
  - aryl aldehyde esters 289
  - bioconjugation 296–297
  - C-to-N ligation 294–296
  - epimerization issue 289
  - extension of 298–302
  - N-to-C ligation 296
  - one-pot ligation 296
  - peptide salicylaldehyde ester 289–294
  - scope and limitations 294
  - solubility issues 298
- Ser64-phosphorylated M2 proton channel 112
- Ser/Thr ligation (STL) 418
- S-ethyl ethanethiosulfinate 127
- Shiga toxin subunit B 198
- short linear peptides 302
- sialyloligosaccharides 105
- side-chain aldehyde 139
- sidechain deprotection 557, 558, 563, 565
- side-chain-protected peptide acid 291
- silyl ester 133
- silyl-protected alkyne 243
- single defined molecular species 5
- single-molecule fluorescence resonance energy transfer (smFRET) 109
- site-specific labeling with isotopes 10
- site-specific labelling 373, 375
- site-specific protein labeling 311
- six-membered tetrahydro-1,3-oxazine
  - structure 302
- small molecules 18
- small protein EETI-II 27
- small ubiquitin-like modifier (SUMO) 111
- small ubiquitin-like protein (SUMO) 505
- S-methyl asymmetric disulfide variant 124
- S-methyl methanethiosulfinate 130
- SMR3B 175
- snow flea anti-freeze protein (sfAFP) 373, 374
- sodium azide afforded azide 130
- sodium benzenesulfinate 147
- sodium 2-mercaptoethanesulfonate (MESNa) 64
- sodium thioacetate 142
- solid phase carbohydrate synthesis 18
- solid-phase peptide ligations (SPCL) 212
  - chemical ligation reactions 260–261
  - N-to-C direction 268
  - post-ligations solid-supported transformations 274–275
  - promises of 259–260
  - requirements 261–262
  - solid support 275–278
- solid phase peptide synthesis (SPPS) 18, 59, 87, 119, 211, 333, 438, 439, 442, 445–447, 449, 455, 456, 473, 535–537, 547
- solid-supported oxidative folding 275
- solubility issues 298
- solubility tags
  - backbone tags 445–449
  - side chain tags 445
  - terminal tags 443–445
- solvent manipulation 185
- sortase 93, 314, 315
- sortase-A 314
- sortase-mediated hydrazide generation 93
- sortase mediated protein hydrazide ligation technique 105
- spherilose resin 276
- sp3-hybridized nitrogen 287
- spinal muscular atrophy 17
- split inteins 309
- Spt-Ada-Gcn5 acetyltransferase (SAGA) complex 498
- Staphylococcus aureus* sortase A (SrtA) 314

- Staudinger-phosphite reaction 539, 543  
 stepwise solid phase synthesis (SPPS) 2  
 stepwise synthesis of polypeptide chains 10  
 L-stereochemistry 362  
 sterically hindered amino acid sites 166  
 sterically hindered C-terminal amino acid residues 170  
 S-(thiobenzoyl)thioglycolic acid 123  
 S-to-N acyl transfer 285  
 stopped-flow techniques 358  
 strain-promoted azide-alkyne cycloaddition (SPAAC) 243, 271  
 subtiligase 317, 318  
 sulfenylation reagent 135, 137  
 sulfhydryl group 311  
*Sulfolobus solfataricus* P2 DNA polymerase IV 188  
 sulfonamide 134  
 sulfonamide resin 215  
 sulfonylethoxycarbonyl-based linker 227  
 sulfonylethoxycarbonyl moiety 238  
 sulfonylethyl carbamate 272  
 sumoylated histones 505, 506, 507  
 superoxide dismutase (SOD) 195  
 superpermeable organic combinatorial chemistry (SPOCC) resin 265  
 Swiss-Prot protein database 197  
 swollen Merrifield resin 91  
 Syk tyrosine kinase 142  
 symmetric and unsymmetrical peptide diselenides 174  
*syn*-alcohol 127  
*synthesized EPO glycoforms*, 105  
*synthetic L-DNA* templates 113  
 synthetic phosphotyrosine 308  
 synthetic polypeptide chain 2  
 synthetic protein molecule 5  
 synthetic proteins 2  
 $\alpha$ -synuclein ( $\alpha$ -Syn) 376, 393, 414
- t**
- tau protein 422, 423  
 Tbeoc-Thz residue 96  
 TCEP-derived selenophosphine 68, 74  
 template assembled synthetic proteins (TASPs) 450  
 TentaGel 19  
 terminally-protected monomer 18  
 2-(*tert*-butyldisulfany)ethyloxycarbonyl (Tbeoc) 96  
 tertiary amide, 124  
 tetrakis(triphenyl phosphine) palladium, 195  
 2,2,6,6-tetramethylpiperidine-1-oxyl radical (TEMPO) 151  
 tetramethyl urea 30  
 tetra-n-butylammonium fluoride (TBAF) 131  
 tetrapeptide 89  
 17 kDa modular tetratricopeptide repeat protein 221  
 tetra-Ub chains 390–392  
   expressed proteins with 400–401  
 tetra-Ub- $\alpha$ -globin-(HA) 399  
 tetra-ubiquitinated  $\alpha$ -globulin 259  
 tetraubiquitinated proteins 395, 400  
 TFA-labile Wang-type linker 265  
 TFA-stable allylic ester 195  
 thermodynamic stabilities 359  
 thermostable DNA polymerase IV (Dpo4) mutants 113  
 thiazolidine (Thz) 135, 196, 221, 287, 470, 471  
   protected building block 134  
   protected cysteine residues 121  
 L-thiazolidine-4-carboxylic acid (Thz) 96  
 thiazolidine/oxazolidine 212  
*trans*-thiazoline 124  
 thioamide isosteres 522  
 thioamino acid-based procedure 173  
 thiobenzamidomalonic ester 123  
*syn*-thiocyanate 127  
 thiodepsipeptide 317  
 thioester 135, 153, 359  
 $\alpha$ -thioesterification 495  
 thioester/thioamino acid ligations 174  
 thioether 212

- thioether-containing isopeptide bonds 111
- thioethylbutylamide (TEBA) 63
- $\beta$ -thiolactone moiety 168
- $\beta$ -thiol Arg building block 139, 140
- $\beta$ -thiol Arg variant 140
- $\beta$ -thiol Asp 135
- $\beta$ -thiol aspartate 123–124
- $\beta$ -thiol aspartic acid 122
- thiolated amino acid 122, 130
- $\gamma$ -thiolated Lys building block 131
- thiolated-proline derivative 138
- $\beta$ -thiol GlcNAc Asn building block 137
- $\gamma$ -thiol Gln variant 139
- $\gamma$ -thiol Glu 135
- $\gamma$ -thiol glutamate 124
- $\gamma$ -thiol Ile variant 127, 130
- $\delta$ -thiol Lys variant 131–133
- $\beta$ -thiol Phe building block 127
- $\beta$ -thiol phenylalanine 121
- $\gamma$ -thiol Pro 138
- $\gamma$ -thiol Pro configuration 138
- thiol-protected cysteinyl peptide thioester segment 235
- $\gamma$ -thiol Pro variant 138
- thiol-selenoester interchange process 63
- thiol-thioester 64
- 2-thiol Trp 144
- $\beta$ -thiol Val 142
- $\gamma$ -thiol Val building block 143
- thio-mercurate 212
- thioprolin-derived peptides 173
- thioredoxin reductase 464
- thiourea 212
- third generation automated fast flow peptide synthesis
  - general lab use 41
  - key findings 32–34
  - model peptides 39
  - new reactor design 36
  - reagent reservoirs 38
  - reagent stability study 43
  - separation of amino acid and activator 35
  - software 38
  - temperature studies 41
- threonine (Thr) 140, 161, 329, 365, 541
- Thr38-Gly62-salicylaldehyde ester 298
- Thr69Xaa analogues 75
- Thz-peptide 4
- Thz-protected segments 267
- tobacco etch virus (TEV) 474
  - protease 193
- transcriptional regulator YAP65 139
- transesterification of acyl azide 90
- transient receptor potential (TRP) 437
- transient thio- or selenoester 61
- transitional state 360–362
- transmembrane (TM) domain 437
  - 1 TM 449–450
  - 2 TM 450–453
  - 3 and more TM 454–456
- transmembrane (TM) peptides 112
  - backbone tags 445–449
  - chemical protein synthesis 449–456
  - purification and handling strategies 442–443
  - side chain tags 445
  - solid phase peptide synthesis 438–442
  - terminal tags 443–445
- transmembrane potassium channel KcsA 186
- trastuzumab 430–432
- triazole 212, 546
  - 1,2,4-triazole 167
- triazole-containing MUC1 polypeptide 272
- tri-Boc-hydrazino acetic acid 336
- trifluoroacetamidomethyl 98
- trifluoroacetic acid (TFA) 185, 438
- trifluoroethanethio (TFET) 162
- 2,2,2-trifluoroethanol (TFE) 442
- trifluoroethanol (TFE) 187
- trifluoroethanol thiol (TFET) 127
- trifluoroethyl thioester
  - Ac-LYRANX-SCH2CF3 176
- trifolitoxin 91
- triisopropylsilane (TIS) 197
- tri-isopropylsilyl group (TIPS) 270



- trimethoxybenzyl alcohol (Tmob-OH)  
     122  
 2,4,6-trimethoxybenzyl isocyanide 139  
 trimethoxybenzyl (Tmob)-protected  
      $\beta$ -thiol Asp derivative 122  
 trimethoxyphenyl thiazolidine 137  
 trimethylsilyldiazomethane (TMSCHN<sub>2</sub>)  
     reagent 215  
*tris*(3-hydroxypropyltriazolylmethyl)amine  
     (THPTA) 261  
*tris*-(2-carboxyethyl)phosphine (TCEP)  
     274  
*tris*-carboxyethylphosphine (TCEP)  
     146  
*tris*-(2-carboxyethyl)phosphine (TCEP)  
     67, 72, 274, 503  
*trityl*-based linker 197  
*trityl*-protected  $\beta$ -thiol aspartate 123  
*trityl*-protected  $\beta$ -thiol aspartate variant  
     124  
*Trp*, and Boc-sarcosinyl-sarcosinyl  
     (Boc-Sar-Sar) 195  
 truncates, 21  
 truncation products 27  
 trypsiligase 314, 318  
 tryptophan 121, 144  
 Tsuji-Trost reaction 263  
 tubulin tyrosine ligase (TTL) 331  
 $\beta$ -turn mimetics 361–362  
 two-photon activated chemokine CCL5  
     103  
 Tyr, Boc-(N-methylamino)butanoyl  
     (Boc-Nmbu) 195
- U**
- Ubiqu[2-76] Ala46Asa 245–246  
 Ubiqu[46-76] hydroxylamine 246  
 Ubiqu[2-45] ketoacid 246  
 ubiquitin (Ub) 364, 383, 386  
     building blocks 387  
 ubiquitinated histone analogs 111  
 ubiquitinated proteins  
     monoubiquitinated proteins 393, 397  
     tetraubiquitinated proteins 395, 400  
 ubiquitination 383–387, 393, 395, 398,  
     401  
 ubiquitin-binding domains (UBDs) 384,  
     390, 401  
 75-mer ubiquitin (Ala46Asa) protein  
     245–246  
 ubiquitin thioester 131  
 ubiquitinated peptide 131  
 ubiquitylated histones 111  
 Ub-thioester 388  
 uncleavable pseudoproline structure  
     287  
 UniProt 2  
 unnatural amino acid (UAA) 92  
 unnatural protein 328  
*N*- $\alpha$ -unprotected amino acids 20, 43  
 unprotected glutamic acid 131  
 unprotected peptide salicylaldehyde ester  
     291  
 unreacted C-terminal peptide segments  
     212  
 urea 227  
 urea-containing peptides 88  
 user interface principles 20  
 USP51 deubiquitinase 111
- V**
- Valco ChemInert 10-position selector  
     valves 24  
 valine 142  
 valinyl-Nbz peptides 169  
 valinyl thioesters 168  
 $\Phi$ -value analysis 360, 361  
 variable number tandem repeat (VNTR)  
     sequence 140  
 Varian Prostar 210 HPLC pumps 47  
 Varian 200 series HPLC pumps 24  
 vascular endothelial growth factor  
     (VEGF) signaling 524  
 vicinal diols 329  
 vinyl glycine derivative 142  
 vMIP I chemokine 267  
 voltage-gated sodium channels (VGSCs)  
     475

**W**

Wang resin 336, 337

water-soluble radical initiator VA-044  
121

Weinreb amide resin 331

**X**

*Xenopus* histone H3 (XH3) 130

XH3 (1-111) thioester 130

X-ray crystallography 7, 109

X-ray structural data 7

**Y**

yes kinase-associated protein (YAP 65)  
361